Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis

Inclusion criteria

• Signed informed consent,
• Patient is eligible for out-patient treatment,
• Men or women between 18 and 80 years of age,
• Diagnosis of left-sided uncomplicated diverticulitis confirmed by ultrasonography (US) and/or computed tomography (CT) according to modified Hinchey classification (stage 1a) or Hansen/Stock classification (stage I/IIa) or Ambrosetti classification (stage mild),
• Presence of significant left lower quadrant pain during the last 24 hours before baseline,
• CRP > ULN and/or leucocytosis (> ULN) at screening visit

Exclusion criteria

• Existing complications of diverticulitis (diverticulitis with associated abscess, fistula, obstruction or perforation),
• Right-sided diverticulitis,
• Previous colonic surgery (except appendectomy, haemorrhoidectomy, and endoscopic removal of polyps),
• Chronic inflammatory bowel disease (such as Crohn's disease, ulcerative colitis) or celiac disease,
• Presence of symptomatic organic disease of the gastrointestinal tract (with the exception of non-bleeding hemorrhoids or hiatal hernia),
• Hemorrhagic diathesis,
• Active peptic ulcer disease,
• Abnormal hepatic function or liver cirrhosis,
• Abnormal renal function,
• Colorectal cancer or a history of colorectal cancer,